Pharsight

Exforge Hct patents expiration

EXFORGE HCT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101599 NOVARTIS Pharmaceutical composition containing anti-hypertensive agents
May, 2023

(4 months ago)

US8475839 NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
May, 2023

(4 months ago)

US8475839

(Pediatric)

NOVARTIS Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
Nov, 2023

(a month from now)

Exforge Hct is owned by Novartis.

Exforge Hct contains Amlodipine Besylate; Hydrochlorothiazide; Valsartan.

Exforge Hct has a total of 3 drug patents out of which 2 drug patents have expired.

Expired drug patents of Exforge Hct are:

  • US8101599
  • US8475839

Exforge Hct was authorised for market use on 30 April, 2009.

Exforge Hct is available in tablet;oral dosage forms.

The generics of Exforge Hct are possible to be released after 16 November, 2023.

Drugs and Companies using AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN ingredient

Market Authorisation Date: 30 April, 2009

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EXFORGE HCT before it's drug patent expiration?
More Information on Dosage

EXFORGE HCT family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic